Pulse nav.journalClub Tendencias Explorar Investigadores

Download the App

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

Política de privacidad

Inicio Explorar nav.journalClub Tendencias

⌘+K

Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease | Synapse

July 17, 2024

Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The efficacy and safety of risankizumab as compared with ustekinumab in patients with Crohn's disease are unknown.

Me gusta

Guardar

Compartir

Me gusta

Guardar

Compartir

Cite This Study

Peyrin‐Biroulet et al. (Wed,) studied this question.

synapsesocial.com/papers/68e5fef1b6db643587592cc7 https://doi.org/https://doi.org/10.1056/nejmoa2314585